Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

NETWORK × Ovarian Neoplasms × toripalimab × Clear all

Phase

Status

Sponsor Class

OTHER 1 NETWORK 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 1

Interventions

Paclitaxel 22 Carboplatin 20 Cisplatin 11 Topotecan 6 Taxes 5 Gemcitabine 5 Docetaxel 5 Doxorubicin 4 Ifosfamide 3 Etoposide 3 Cyclophosphamide 3 Chemotherapy, Adjuvant 3 rubitecan 2 paclitaxel poliglumex 2 liposomal doxorubicin 2 Surgical Procedures, Operative 2 Psychiatric Rehabilitation 2 Polymerase Chain Reaction 2 Filgrastim 2 Erlotinib Hydrochloride 2 Bevacizumab 2 vandetanib 1 trioctyl phosphine oxide 1 toripalimab 1 sargramostim 1 rilotumumab 1 pegfilgrastim 1 oregovomab 1 motesanib diphosphate 1 durvalumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04918186 2026-02-12

IPROC

Canadian Cancer Trials Group

Phase 2 Recruiting

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡